Start-up Profile – CRED iQ

Last year we reviewed a new entrant into the financial information landscape, with the start-up Sigma Ratings which exists to provide focused and specialised information regarding anti-money laundering and its effects on creditworthiness (amongst a number of other aims). In today’s short post we will be introduced to another start-up aiming to impact the marketplace, this time in the field of information relating to commercial real estate intelligence, which is particularly apt given the market shift in focus to commercial mortgage-backed securities over the past few years – that company is CRED iQ.

 

CRED iQ, founded by Bill Petersen and Michael Haas, has the expressed aim of providing the marketplace with a flagship platform which provides for interactive commercial real estate valuation, CMBS monitoring, and also involves a ‘lead generation platform delivering objective risk assessments to CRE (Commercial Real Estate) and capital market investors’. The innovative platform provides users with commercial real estate valuations that is based on in-depth and relevant market data, trend analysis, and more than 20 years of valuation experience, whilst the interactive valuation scenarios (MyQ) enables users to navigate user-friendly software that can adjust CRED iQ valuations and observe the adjustments across loans, deals, and portfolios. There are also elements of the platform that provides information on loss projections, portfolio analytics, and there is also the opportunity to set real-time alerts so that changes in the marketplace that may be relevant to a portfolio can be incorporated instantly into the decision-making process. Additionally, the company is launching what it calls Investment Quality Scores (iQ), which it says are ‘numerical tranche and deal level objective risk assessments free from market perceived conflicts of interest’.

 

The company states that it serves a number of industries, including mortgage brokers, leasing agents, investment sales, and capital markets amongst a large list of others. The independence that the company is seeking to display should be of real benefit to those potential industries that may use the new company’s platform and services. To subscribe to the platform, the rates are $149 per month per user for the Standard package, and $249 per month per user for the Ultra package. The new company is growing well, as evidenced by a current recruitment drive for software engineers and their recent contribution to a Wall Street Journal article which saw their valuation of the Fontainebleau Hotel in Miami incorporated into the analysis being developed by the WSJ. For those readers who may be interested in learning more about the company and the platform it offers, there is a free trial available. If more information is required, then the company can be contacted here.

 

The aim to inject impartial and considered information into the CRE landscape is a welcome one, particularly as the company aims to develop useful information that is free from the conflicts of interest that can cause so much damage in a field such as this one. Hopefully the company will continue to grow and we shall monitor its progress here in Financial Regulation Matters. You can follow the company on LinkedIn here.

 

Keywords – CRED iQ, Analytics, CMBS, Commercial Real Estate, @finregmatters.


Comments

Post a Comment

Popular posts from this blog

Lloyds Bank and the PPI Scandal: The Premature ‘Out of the Woods’ Rhetoric

Image
Today’s very short post focuses upon the news that the Financial Conduct Authority (FCA) has recently extended the deadline to claim compensation for mis-sold ‘Payment Protection Insurance’ (PPI). Whilst a lot of financial institutions will have to prepare to offset the extended deadline, it is Lloyds that has grabbed the business headlines by apportioning an extra £350 million to offset any further claims that may be made of it – however, this comes only a week or two after the Bank posted its best performance figures in over a decade, as was previously discussed in Financial Regulation Matters . This post will therefore argue that the rhetoric being advanced recently regarding Lloyds – rhetoric like Lloyds represents ‘ a modern day success story ’ is wide of the mark and creates a false sense of security that we simply cannot afford to believe in. The ‘ robust recovery ’ was heralded far and wide upon the publication of Lloyds Bank’s financial performance for the previous fi
Read more

The Analytical Credit Rating Agency: A New Entrant That Will Further Enhance Russia’s Isolation

Image
This short post is based upon a forthcoming article by this author that examines the viability of the latest entrant into the credit rating arena, the Analytical Credit Rating Agency (ACRA). The article, which is due to be published in the European Company Law Journal (and is available here in a pre-published version), looks at the chances of the ACRA succeeding when viewed within the parameters of perception , an aspect that underpins the credit rating sector. For this post, the focus will be upon introducing the ACRA, and then on examining the effect it may have upon the wider political issues affecting the Russian Federation. The Analytical Credit Rating Agency was established in November 2015 and comprises of 27 major Russian companies and financial institutions that serve as its shareholders. The agency, which became the first rating agency to receive accreditation from the Russian Central Bank under the new N 222-FZ Law which was designed to protect investors, has a re
Read more

The Case of Purdue Pharma, the Sackler Family, and the Opioid Crisis

Image
In the first of two short posts today, we will look at the case of the billionaire Sackler Family and their remarkable effect upon American society. The family, who own Purdue Pharma amongst a list of other ventures, have this week seen a massive legal action taken against them by the State of New York who argue that the company is ‘ responsible for the opioid epidemic ’ sweeping through the United States. The attorney-general for New York has called the lawsuit the ‘ nation’s most extensive ’ with respect to the pharmaceutical industry and comes right on the heels of a $270 million suit that was settled in the State of Oklahoma on exactly the same grounds. Whilst the company and the billionaire family who own it did not admit guilt (settling parties rarely do, hence why they settle outside of court) it has potentially opened the trapdoors for litigation. It comes as no surprise then that the company is reportedly considering bankruptcy proceedings in the face of such an onsl
Read more